Seer (SEER) Q2 Revenue Jumps 32%
Seer (NASDAQ:SEER), a life sciences technology firm specializing in advanced proteomics, released its second quarter results for fiscal 2025 on August 6, 2025. Seer reported GAAP revenue of $4.1 million, topping consensus estimates of $3.75 million by $0.35 million and marking a 32% increase from the prior-year period. Operating expenses dropped 21% year-over-year, and the GAAP net loss per share was $(0.33). The period showed continued advancement in commercial execution and technology rollout amid ongoing macroeconomic pressures, but the company remains unprofitable overall (GAAP net loss).
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Seer designs and sells advanced proteomics research solutions. Its flagship Proteograph Product Suite relies on proprietary nanoparticles to help researchers study a wide array of proteins across complex biological samples. This platform powers large-scale protein analysis that can lead to discoveries in disease mechanisms, diagnostics, and precision medicine.
Source Fool.com
